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a  b  s  t  r  a  c  t
Phosphodiesterases  (PDEs)  regulate  the intracellular  levels  of cAMP  and  cGMP.  The  great clinical  success
of the  PDE5  inhibitors,  Sildenafil  (Viagra),  Vardenafil  (Levitra)  and Tadalafil  (Cialis)  has  led  to  an  increas-
ing  interest  for this  class  of enzymes.  Recent  studies  have shown  a  correlation  between  tumor  growth
and  PDE5  overexpression,  making  PDE5-selective  inhibitors  promising  candidates  for  cancer  treatment.
The  search  for such  inhibitors  rests  today  on  radioactive  assays.  In this  work,  we  exploit  the  conserved
catalytic  domain  of  the enzyme  and  propose  a  faster  and  safer  method  for  detecting  the  binding  of ligands
and  evaluate  their  affinities.  The  new  approach  takes  advantage  of Förster  Resonance  Energy  Transfer
(FRET)  between,  as the  donor,  a fluorescein-like  diarsenical  probe  able  to covalently  bind  a  tetracysteine
motif  fused  to the  recombinant  PDE5  catalytic  domain  and, as  the  acceptor,  a rhodamine  probe  covalently
bound  to  the  pseudosubstrate  cGMPS.  The  FRET  efficiency  decreases  when  a competitive  ligand  binds
the  PDE5  catalytic  site  and  displaces  the  cGMPS-rhodamine  conjugate.  We  have  structurally  investigated
the  PDE5/cGMPS-rhodamine  complex  by  molecular  modelling  and  have  used  the  FRET  signal  to  quan-
titatively  characterize  its  binding  equilibrium.  Competitive  displacement  experiments  were  carried  out
with tadalafil  and  cGMPS.  An  adaptation  of the  competitive-displacement  equilibrium  model  yielded  the
affinities for PDE5  of  the  incoming  ligands,  nano-  and  micromolar,  respectively.
© 2017  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Phosphodiesterase enzymes (PDEs) are phosphohydrolases that
selectively hydrolyse ubiquitous second messengers (cGMP and
cAMP) thereby regulating their signaling pathways and down-
stream biological effects [1–3]. PDEs accomplish different biological
roles, including smooth muscle relaxation and blood pressure
Abbreviations: PDE5, Phosphodiesterase 5; PDE5C, Phosphodiesterase 5 cat-
alytic domain; PDE5C-TC, phosphodiesterase 5 catalytic domain modified with
a  tetracysteine tag; PDE5C-TC-FlAsH, complex obtained by conjugation of the
FlAsH fluorophore to Phosphodiesterase 5 Catalytic domain modified with a
tetracystein tag; FlAsH-EDT2, 4′5′-Bis(1,3,2-dithiarsolan-2-yl)-fluorescein; cGMPS,
2′-(6-Aminohexylcarbamoyl)guanosine-3′ ,5′-cyclic monophosphorothioate.
∗ Corresponding authors.
E-mail addresses: giulia.dirocco@unimore.it (G. Di Rocco),
glauco.ponterini@unimore.it (G. Ponterini).
regulation, platelet aggregation and disaggregation, ion channel
conductance and neurotransmission, cell growth, apoptosis and
cellular mobility and contractility [2]. PDEs have been exploited
pharmacologically for more than half a century and some of the
most successful drugs worldwide like Sildenafil (Viagra), Varde-
nafil (Levitra) and Cialis (tadalafil) affect PDE5 function. Therefore,
these drugs are subjected to extensive mechanistic investigations
and clinical trials [6]. PDEs comprise a 21-gene super family cat-
egorized into 11 families. Among them, type 5 phosphodiesterase
(PDE5), of which three isoforms (PDE5A1, PDE5A2 and PDE5A3)
are known, is responsible for cGMP hydrolysis [1–3]. PDE proteins,
with a few exceptions, contain a highly conserved catalytic domain,
but differ in the regulatory domain at the N-terminus [3]. Recently,
functional variants of PDE genes have been suggested to play a
role in predisposition to tumors [1,4–7]. These activities would
strongly benefit from the development of fast, sensitive and reli-
able tools for rapidly screening potential PDE5 inhibitors. Herein,
https://doi.org/10.1016/j.jpba.2017.11.014
0731-7085/© 2017 Elsevier B.V. All rights reserved.
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we demonstrate that the tetracysteine-tag technology applied to
the PDE5 catalytic domain (PDE5C, coding region Glu536-Gln860)
is a promising approach in this respect. This method exploits the
binding of a fluorescent probe, the fluorescein diarsenical hair-
pin binder (FlAsH), to a short peptide sequence which includes
four cysteine residues, namely Cys-Cys-Xaa-Yaa-Cys-Cys (CCXYCC,
in which X and Y denote any amino acid) to be engineered on
the target protein [8,9]. Site-selective labelling of proteins in liv-
ing cells can be achieved with this method that has been applied
to address a variety of issues involving detection of protein-
protein interactions [10–12]. This molecular technology has also
been recently employed to detect and quantitatively character-
ize the engagement of a small-molecule inhibitor with its target
enzyme in a cell lysate [13] but, to our knowledge, it has never
be applied to purified enzyme. We  have expressed the catalytic
domain of the PDE5A2 (identifier: O76074-2)  with a genetically
encoded 6xHis tag at the N-terminus and the 6-amino-acid motif
CCPGCC (TC) at the C terminus. This tetra-cysteine motif proved
able to covalently bind the biarsenical fluorescein probe (FlAsH-
Fig. 1) [9,11]. The complex between the fluorescent protein and
the non hydrolysable pseudosubstrate cGMPS, tagged with rho-
damine, was obtained and used for displacement studies by the
known PDE5 inhibitor tadalafil and by cGMPS. A Förster resonance
energy transfer (FRET)-based determination produced the binding
constant for the fluorescent cGMPS-rhodamine pseudosubstrate.
Similarly, in experiments where either tadalafil or cGMPS were
added to PDE5C-TC-FlAsH/cGMPS-rhodamine complex solutions,
the observed decrease in the efficiency of FRET between FlAsH
and rhodamine enabled us to prove the occurrence of ligand dis-
placement as well as estimate the affinity constant of the two
ligands for the PDE5 catalytic site. In addition, we  derived struc-
tural information on the binding mode of the pseudosubstrate by
molecular docking calculations of the cGMPS-rhodamine at the
modelled PDE5A2 catalytic site (PDE5C). Because the presently
available X-ray diffraction structures for PDEs are limited to the cat-
alytic domains, the homology model of the related human PDE5A2
isoform created by us was limited to this portion of the protein.
2. Materials and methods
2.1. Materials
Molecular Biology Reagents: Primers for the cloning of
the PDE5A2 catalytic domain were purchased from Eurofins
Genomics S.r.l (Italy). The plasmid pLATE 52, IPTG (!-d-
thiogalactopyranoside), !-mercaptoethanol and phenylmethylsul-
fonyl fluoride (PMSF) were all purchased from Thermo Fisher
Scientific (Waltham, MA,  USA). Tris(2-carboxyethyl)phosphine
hydrochloride (TCEP) was purchased from Sigma-Aldrich (St. Louis,
MO,  USA)
Ammonium bicarbonate (AMBIC), dithiothreitol (DTT), iodoac-
etamide (IAA) were all purchased by Sigma-Aldrich. FlAsH −EDT2
was from Santa Cruz Biotechnology (Dallas, TX, USA).
2′-(6-Aminohexylcarbamoyl)guanosine-3′,5′-cyclic monophos-
phorothioate (RP-2′-AHC-cGMP) and the sulforhodamine B-X
succinimidyl ester (Rhodamine Red-XTM) were purchased from
BioLog (Bremen, Germany) and Thermo Fisher Scientific, respec-
tively. Tadalafil was purchased from Sigma-Aldrich.
The solvents Trifluoroacetic acid (TFA), Acetonitrile (CH3CN) and
N,N-Diisopropylethylamine (DIPEA), were purchased from Sigma-
Aldrich.
2.2. Production of recombinant PDE5C-TC
The wild type PDE5 catalytic domain (PDE5C), Glu536-Gln860
coding region, was  constructed from the full length human PDE5A2
cDNA (kindly provided by Federica Barbagallo of the “La Sapienza”
University, Rome) as the template. The gene fragment coding for
PDE5C was  amplified by PCR (Polymerase Chain Reaction) using
the following primers:
FW 5′-GGTTGGGAATTGCAAGAAACAAGAGAGCTACAGTCG-3′;
RV 5′-GGAGATGGGAAGTCATTAGTTCCGCTTGGCCTGGCCG-3′.
The DNA fragment was then subcloned into the His-
tagged expression vector pLATE 52. The positive clones were
sequenced and then transformed into E. coli BL21 cells (Strata-
Fig. 1. Schematic outlook of the main structural features of the proposed technology. Bottom: details of the PDE5C-TC a.a. construct with, in grey, the sequence genetically
encoding the 6xHis tag added for the purification of the protein and, in blue, the sequence genetically encoding the tetracysteine tag added at the C-terminus. The WELQ
sequence (light green) is necessary for a further proteolytic cleavage of the 6xHis tag. Zoomed section: superimposition of the derived PDE5A2 model (magenta) on the
PDE5  coordinates (light yellow). The co-crystallyzed inhibitor Sildenafil is depicted in stick mode (C atom; green). Mg2+ and Zn2+ metal ions are shown in cyan and green,
respectively, as space filling. A, Acceptor: The synthesized pseudosubstrate (cGMPS)-rhodamine (the FRET acceptor) conjugate. D, Donor: Binding mode of the biarsenical
FlAsH  probe to the tetracysteine tag. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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gene, La Jolla, CA). A second clone coding for the PDE5C-TC
(the PDE5 catalytic domain with the tetracysteine tag) was
obtained using the above mentioned forward primer and a new
reverse primer containing the oligonucleotides triplets coding
for the TC-motif (GGCCPGCCGG): RV5′- ttaACCACCACAGCAGCC-
CGGGCAACAGCCACCgttccgcttggcctggc −3′.
The amplified fragment was then cloned into pLATE 52 vector.
The E. coli transformants containing the PDE5C-TC-motif were
grown in enriched LB medium with 0.4% glucose and 1 mM MgSO4
at 37 ◦C, and the protein expression was induced (O.D.600∼=0.8)
with 0.1 mM  (IPTG at 25 ◦C), overnight. Cells were harvested by
centrifugation at 4500 rpm for 10 min  at 4 ◦C. Crude extracts were
resuspended directly in solvent A (20 mM Tris base; pH 8.0;
0.05 M NaCl; 15 mM imidazole; 1 mM !-mercaptoethanol; 1 mM
phenylmethylsulfonyl fluoride) and were purified by AKTA® FPLC
(GE-Healthcare, Little Chalfont, UK) using a column HisTrap FF
crude (GE Healthcare Little Chalfont, UK) for IMAC chromatography
perfused at a flow rate of 3 ml/min with a mobile phase-containing
solvent A and a linear gradient from 0% to 100% of solvent B (20 mM
Tris base, pH 8.0; 0.3 M NaCl 150 mM imidazole and 1 mM !-
mercaptoethanol) for elution of the proteins. The proteins were
eluted at 98% of solvent B. For further spectrofluorometric mea-
surements !-mercaptoethanol was replaced by 1 mM TCEP.
The two proteins (PDE5C and PDE5C-TC) were analysed by SDS-
PAGE, by western blot and by mass spectrometry after tryptic
digestion and quantified by Lowry’s method.
2.3. Tryptic digestion
The pure proteins were subjected to digestion with TPCK mod-
ified sequencing grade trypsin (final enzyme to substrate ratio
1:50 w/w) at 37 ◦C overnight. 12 "g of protein extract were treated
with 5 "l of ammonium bicarbonate (AMBIC) 100 mM,  reduced
with dithiothreitol (DTT, 10 mM,  1 "l in AMBIC 100 mM)  at 56 ◦C
for 30′ and alkylated with 2-iodoacetamide (55 mM,  1 "l in AMBIC
100 mM)  at room temperature (RT) in the dark for 1 h. The excess
of alkylating agent was quenched with 10 "l DTT 10 mM at RT for
10′ [20]. Samples were then acidified with 5% formic acid (FA) solu-
tion and dried in a vacuum evaporator. Peptides were suspended in
30 "l of 1% FA/acetonitrile 98:2 solution and injected to a LC-ESI-Q-
TOF mass spectrometer (Agilent Technologies, Santa Clara CA,USA).
The raw data were searched against Swiss Prot database (Swis-
sProt 57.15.fasta) using an in-house made MASCOT Server (version
2.4, Matrix Science, UK) [14].
2.4. PDE enzymatic assay
The activities of PDE5C and PDE5C-TC were measured with
the method described by Thompson and Appleman [15] in 60 mM
Hepes pH 7.2, 0.1 mM EGTA, 5 mM MgCl2, 0.5 mg/ml bovine serum
albumin, and 30 "g/ml soybean trypsin inhibitor, in a final volume
of 0.15 ml.  The reaction was started by adding [3H]cGMP substrate
at indicated concentrations. Samples were incubated at 30 ◦C for
15 min. The reaction was  stopped by the addition of 0.1 N HCl and
neutralized with 0.1 N NaOH in 0.1 M Tris-HCl pH 8.0. Subsequently,
2 mg/ml  of 5′-nucleotidase (snake venum from Crotalus atrox;
Sigma-Aldrich) in 0.1 M Tris-HCl pH 8.0 were added. Samples were
gently mixed and incubated at 30 ◦C for 30 min  to allow complete
conversion of 5′-nucleotide to its corresponding nucleoside. Unhy-
drolysed cyclic nucleotide and corresponding nucleoside were
separated by DEAE-Sephadex A-25 columns. The eluate was mixed
with scintillation liquid ULTIMA GOLD (PerkinElmer Waltham, MA,
USA) and counted on a Tri-Carb 2100TR Liquid Scintillation Counter
(2000CA; Packard Instruments, Meriden, CT)]. PDE activity and KM
values were expressed as mean ±SD of three independent experi-
ments.
2.5. Spectroscopic measurements
UV–vis spectra were recorded with a Varian Cary® 100 UV–vis
(Varian, Inc.) spectrophotometer. Fluorescence measurements
were performed with a Horiba Jobin-Yvon FluoroMax3 spectroflu-
orometer (Horiba Scientific, Kyoto, JP). Samples were contained
in 4 × 10 mm2 quartz cuvettes. UV–vis absorption spectra for
PDE5C/PDE5C-TC were recorded in the range between 230 and
350 nm,  using the #280 = 38430 M−1 cm−1 to determine the pro-
tein concentration (800 "l of a PDE5TC-FlAsH solution in 20 mM
Tris base; pH 8.0; 0.15 M NaCl; 1 mM TCEP). For the emission
spectra, the excitation wavelength was  set at 465 nm, i.e., the
wavelength where the relative contribution of the absorption of
the energy transfer acceptor (rhodamine) relative to the donor
(FlAsH) was minimum; the emission spectra were collected from
480 to 700 nm.  Fluorophore concentrations were determined spec-
trophotometrically using the following extinction coefficients: #509
(FlAsH+ FLNCCPGCCMEP) = 64000 M−1 cm−1 and, for tetramethyl-
rhodamine, closely related with the employed Rhodamine Red-XTM
probe, #574 (tetramethylhodamine) = 85000 M−1 cm−1.
All measurements were performed, in 20 mM Tris base, pH 7.5,
plus 0.15 M NaCl, and 1 mM TCEP, and were carried out at room
temperature (22 ± 2 ◦C).
2.6. cGMPS-rhodamine synthesis
cGMPS-rhodamine crude product was purified by preparative
reversed-phase HPLC using a Water Delta Prep 3000 system with
a Waters PrepLC 40 mm Assembly column C18 (30 × 4 cm, 300 Å,
15 "m spherical particle size column). The column was perfused at
a flow rate of 2 ml/min, with a mobile phase-containing solvent A
(100% v/v of H2O; 0.1%v/v TFA), and a linear gradient from 0% to
100% of solvent B (60% v/v of CH3CN;40%v/v H2O; 0.1%v/v TFA)
in 25 min  was used for elution of the compound. HPLC analysis
was performed using a Beckman System Gold with a Hypersil BDS
C18 column (5 "m;  4.6 × 250 mm).  Analysis was performed with
the solvent system reported above programmed at flow rates of
1 ml/min and with a linear gradient from 0% B to 100% B in 25 min.
To a stirred solution of RP-2′-AHC-cGMP (0,005 mmol) in a 1:1 mix-
ture of CH3CN/H20 (1 ml), rhodamine Red-XTM (0.005 mmol) and
DIPEA (0.01 mmol) were added. The fluorescent violet solution was
stirred in the dark at room temperature for 30 min. After this time,
analytical HPLC showed a total conversion of the starting materi-
als. The reaction mixture was  directly injected in preparative HPLC
giving the desired cGMPS-rhodamine as a violet solid (53% yield)
after lyophilisation (analytical HPLC and mass spectra are available
as Supplementary material Fig. S1). cGMPS-rhodamine showed
>95% purity and its molecular weight ([M + H]+ 1157,3509 g/mol)
determined by electrospray ionisation (ESI) (MICROMASS ZMD
2000, Waters Alliance, Milford, MA,  USA) resulted in line with the
expected molecular formula (1156,27 g/mol).
2.7. In silico evaluation of PDE5 – cGMPS-rhodamine interaction
The chemical structure of cGMPS-rhodamine was built, param-
eterized (Gasteiger-Hückel method) and energy minimized within
Sybyl-X 1.0 using the Tripos force field [16]. PDE5A2 has been mod-
elled on the basis of the PDE5 X-ray data in complex with Sildenafil,
downloaded from the protein databank (pdb code 1TBF; resolu-
tion = 1.30 Å) [17]. The sequence alignment was derived on the basis
of the Blosum62 matrix by means of the MOE  software [18]. The
final homology model was  derived using MOE, following a proce-
dure previously adopted for other case studies [19].
A thorough evaluation of the final PDE5A2 model was per-
formed using Ramachandran plots, and also exploring the contact
energy values and the rotamer profile by a comparison with
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those evaluated for the X-ray template. Docking studies of cGMPS-
rhodamine have been performed by means of the Surflex docking
module implemented in Sybyl-X1.0. Surflex-Dock uses an empir-
ically derived scoring function based on the binding affinities of
protein-ligand complexes and on their X-ray structures. This kind
of parameter is a weighted sum of non-linear functions involv-
ing van der Waals surface distances between the appropriate pairs
of exposed protein and ligand atoms, including the hydrophobic,
polar, repulsive, entropic and solvation and crash terms. Finally,
the derived protein-ligand complex stability was assessed using a
short molecular dynamics (MD), ∼1 ps run, at constant tempera-
ture, followed by an all-atom energy minimization (LowModeMD
implemented in MOE  software), as some of us previously discussed
in other homology modelling-based studies [20]. All calculations
were carried out on a standard personal computer running under
Windows XP.
2.8. PDE5-TC labeling
The labelling of PDE5C-TC with FlAsH was obtained by incu-
bating the protein (20 "M)  with 1.5 equivalents of FlAsH-EDT2
(Life Techonologies Carlsbad, CA, USA) in 20 mM  TRIS, 0.15 M NaCl,
1 mM TCEP, pH 8 for 1 h at room temperature in the dark [8]. The
reaction mixture was applied to a G25 Sephadex (GE Healthcare,
Little Chalfont, Buckinghamshire, UK) column material to remove
the unbound FlAsH-EDT2. The eluted Protein-FlAsH complex was
checked by UV–vis and SDS-PAGE (12% acrylamide under reducing
conditions) [9].
2.9. FRET and displacement experiments
The non-radiative energy transfer (FRET) between the PDE5C-
TC-bound excited donor (FlAsH) and the cGMPS-bound rhodamine
acceptor was measured using a Horiba Jobin-Yvon FluoroMax3
spectrofluorometer (Horiba Scientific, Kyoto, JP). The FRET effi-
ciency, that is proportional to the fraction of PDE5C-TC-FlAsH
bound to cGMPS-rhodamine, was determined by measuring the
emission intensities of the FlAsH donor (IF) at 530 nm and the
rhodamine acceptor at 600 nm (IR) following progressive cGMPS-
rhodamine additions. The fluorescence spectra were obtained at
$exc = 465 nm,  a wavelength selected in order to afford the maxi-
mum IF/IR relative excitation. All spectroscopic experiments were
carried out in 20 mM Tris base, 0.15 M NaCl, and 1 mM TCEP at the
carefully controlled pH = 7.5. Data analysis and the determination of
the Kd value for the PDE5C-TC-FlAsH/cGMPS-rhodamine complex,
hereafter called ‘complex 1’, are described in detail in the results
section.
To investigate the decrease in FRET efficiency due to displace-
ment of the pseudosubstrate upon competitive inhibitor binding,
solutions of tadalafil and cGMPS were progressively added to the
complex 1 solutions and the IF/IR (donor/acceptor) intensity ratio
value was analyzed as a function of the added inhibitor concen-
trations. Typical protein cGMPS-rhodamine concentrations were
between 5 and 20 "M.
Data handling and Kd calculation for the competitor are based
on the original articles by Wang and co-workers, in which the
classical quadratic equation becomes cubic due to the presence
of three components in solution, namely the two ligands (cGMPS-
rhodamine and inhibitor) and the protein, generating a three-state
equilibrium binding model [21,22]. We  chose to compute the con-
centration of complex 1 (‘PA’ in Wang’s expressions) in terms of the
ratio of the 530 nm (IF) to 600 nm (IR) emission intensities, R, using
Eq. (1):
R = R
∞ (1 − f )
1 + R∞ · a · f (1)
where R∞ is the value of R at the end of the displacement,
f = [complex 1]/[PDE]tot is the fraction of protein bound to cGMPS-
rhodamine and a = !R%R/!F%F, with !R,F indicating the emission
quantum yields of the two  probes and %R,F the instrumental sen-
sitivities of the employed detection channel at 600 nm (R) and
530 nm (F). We  estimated this parameter to hold 0.5 in our con-
ditions. A derivation of Eq. (1) is given in the Supplementary
information (Expression of the donor/acceptor emission intensity
ratio in terms of the concentration of complex 1). Wang’s equation
(Eq. (14) in ref. [21]) was then employed to compute the concen-
tration of complex 1 (PA according to Wang) in terms of the known
total concentrations of the protein and of the two competing lig-
ands and the dissociation constants of the two complexes. The R
values computed this way  were visually compared with the exper-
imental R values, thus enabling us to estimate the Kd value for
the complex (complex 2) with the incoming ligand (KB in Wang’s
treatment).
3. Results and discussion
3.1. Protein characterization
The PDE5A gene encodes three isoforms (PDE5A1, PDE5A2 and
PDE5A3), generated through alternative splicing of the first exon of
the PDE5A gene. These isoforms share the same C-terminal catalytic
domain (C), differing only in the N-terminal portion. In this work,
the sequence corresponding to the C-terminal catalytic domain of
PDE5A2 (aa 536-860) was  cloned in two  different forms: the wt
(PDE5C) and the tetracysteine-tagged catalytic domain (PDE5C-
TC). The TC (CCPGCC) motif was successfully introduced at the
C-terminus of the PDE5C domain by PCR. Insertion was confirmed
by DNA sequencing. The proteins were expressed in −E. coli and
successfully purified by a two-step purification procedure lead-
ing to more than 90% of pure product. The purified proteins were
analyzed by ESI Q-TOF MS  to assess protein identity. The pure pro-
teins were digested with trypsin and analyzed by ESI Q-TOF MS-MS
yielding 80% sequence coverage with the human PDE5A2 catalytic
domain.
The purified proteins were tested for enzymatic activity using
1 "M [3H]cGMP as the substrate. PDE5C and PDE5C-TC were
similarly active with 0.17 ± 0.04 and 0.18 ± 0.07 "moles of cGMP
hydrolised/min/mg, respectively. These data are in accordance
with the activity of full length PDE5 [23] and demonstrate that
dimerization is not required for PDE5 catalytic activity, as both
recombinant catalytic domains were monomeric [24,25]. Moreover
the Michaelis constant for PDE5C-TC was determined (Fig. S2 Sup-
plementary information): KM = 10.7 ± 1.4 "M.  This value is similar
to that obtained with the purified full length enzyme [2].
The SDS-PAGE analysis of PDE5C and PDE5C-TC-FlAsH outlined
the presence of the green fluorescent bands in lanes containing
the PDE5C-TC-FlaAsH adductconfirming the labelling of the PDE5C-
TC [9]. The presence of such fluorescent bands in the gel obtained
under reducing conditions confirms the covalent character of the
bonding of FlAsH to PDE5C-TC. Unspecific labelling was negligible
under our experimental conditions. (Fig. S3-Supplementary infor-
mation). Moreover, the covalent binding of FlAsH did not modify
the kinetic properties of the enzyme. Indeed, the KM of PDE5CTC-
FlAsH, 12.8 ± 2.2 "M,  was  not significantly different from that of
PDE5C-TC (Fig. 2 Supplementary information).
Formation of the PDE5C-TC-FlAsH adduct was indicated in the
UV–vis absorption spectrum by the appearance of a band typi-
cal of cysteinebound to FlaAsH with maximum at 509 nm (Fig.
S4Supplementary information), and was confirmed by the appear-
ance of a fluorescence emission band with maximum at 530 nm
whose intensity increased with time for 30–40 min  in agree-
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ment with the observed behaviour of other FlAsH complexes
[26]. In order to remove residual traces of nickel ions bound
to the tetracysteine-tag during the IMAC chromatography, the
protein was treated with 0.5 mM EDTA before labelling it. Addi-
tionally, because of the FlAsH-EDT2 large excess, emission from
unbound tag and radiative transfer to the rhodamine acceptor
would interfere in subsequent experiments aiming at determining
FRET efficiencies. To remove the unbound FlAsH-EDT2 we passed
the protein+probe solution through a desalting chromatography
column. This treatment, together with the pre-treatment with
EDTA, led to a spectrophotometrically determined (bands at 280
and 509 nm in Fig. S4) 1:1 PDE-TC/FlAsH concentration ratio, and
caused an increase in the observed FRET efficiency by a factor of 10.
3.2. PDE5 homology modeling and docking studies
We  first discuss the PDE5A2 homology model derived from
the X-ray crystallographic data of the available PDE5 in order to
explore the putative binding mode of the fluorescent ligand cGMPS-
rhodamine through docking calculations. This approach expected
to yield some valuable, although preliminary information, for the
design of novel ligands.
The PDE5A2 homology model was built following the pro-
cedure that some of us recently reported for other PDEs [19].
Briefly, the amino acidic sequence of the PDE5A2 catalytic site was
aligned with that of the PDE5 X-ray structure (pdb code: 1TBF;
resolution = 1.30 Å) [17] (Fig. S5 Supplementary information). The
reliability of the alignment demonstrated by the high value of the
pairwise percentage residue identity calculated between the two
proteins, PPRI = 93.3%.
Then, the derived PDE5A2 model was superimposed on the coor-
dinates of PDE5 (Fig. S10 Supplementary information), used as a
template, and a good C-atom aligment root-mean-square deviation
value was obtained (RMSD = 0.456 Å). The geometry and the related
backbone conformation of the model, inspected by Ramachandran
plot (see Fig. S6, Supplementary information), showed no outliers,
thereby yielding a good validation of the computational protocol. In
addition, the structural reliability of the model has been evaluated
by comparing the energy profiles of the derived PDE5A2 catalytic
site and of the template, PDE5. In general, high negative values and
positive energy terms correspond to residues which are expected
to be oriented toward a hydrophobic and a hydrophilic environ-
ment, respectively. Notably, the observed energetic profile of the
two proteins proved to follow the same polar trend (see Fig. S7,
Supplementary information). Also, model quality estimation for
the protein side-chains was  performed by the rotamer energy pro-
file; this showed no outliers, since all the residues fell within the
recommended energy values (Fig. S8, Supplementary information).
Taken together, these data validate the PDE5A2 model. This
was then employed to explore the putative binding mode of
cGMPS-rhodamine. For this kind of analysis, we considered that
the enzymes included in the PDE5A family are characterized by
highly conserved pockets classified as a metal-binding pocket (M
pocket), a solvent-filled side pocket (S pocket) and a third region
known as hydrophobic clamp (Q pocket). These cavities include:
(i) H613, H617, H653, D654, H657, N662, L681, E682, D724, L725,
D764 (M pocket); (ii) G659, N662, E785, F786, Q789, T802, M805
(S pocket); (iii) Y612, L765, A767, I768, Q775, I778, A779, V782,
A783, L804, I813, M816, Q817, F820 (Q pocket), as described for
the PDE5 isoform [27]. The results reported by Card [27], as well
as a number of crystallographic data about PDE5 complexes, high-
light the key role played by a glutamine residue in the Q pocket
engaged in the ligand binding. Accordingly, the inhibitor Sildenafil
co-crystallized in the PDE5 catalytic site of 1TBF employed in this
work, exhibits two  H-bonds with Q817 (see Fig. S9, Supplementary
information). Based on this information and on a superimposition
of the obtained PDE5A2 on the X-ray structure of PDE5, we out-
lined the corresponding binding site of the modelled protein, in
order to proceed with docking calculations of cGMPS-rhodamine.
Our results revealed a conserved H-bond with the aforementioned
glutamine residue Q817 thanks to the purine cycle that exhibits
a position similar to that of Sildenafil (inhibitor crystallized with
PDE5), while the dioxaphosphinine substituent properly moves
towards the metal pocket. Conversely, the bulky rhodamine portion
proved to lay outside the enzyme cavity (Fig. 2).
Fig. 2. Docking mode of cGMPS-rhodamine (in green) and Sildenafil (in khaki) within the modelled PDE5A2 catalytic site. The most important residues are labelled. Mg2+
and Zn2+ metal ions are shown in cyan and yellow, respectively, as space filling. (For interpretation of the references to colour in this figure legend, the reader is referred to
the  web version of this article.)
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Fig. 3. A) Scheme of the FRET experiment between PDE5C-TC-FlAsH (the excitation energy donor) and cGMPS-rhodamine (the acceptor). B) Emission spectra measured
during  the titration of PDE5C-TC-FlAsH with cGMPS-rhodamine. [FlAsH] = 7 "M,  [cGMPS] = 0 (dashed line) ÷ 13 "M.  The arrows indicate the decrease in FlAsH (D) emission
due  to cGMPs-rhod (A) addition. $exc = 465 nm.  C) Dependence of %, the fraction of occupied PDE5-TC binding sites, on the concentration of added cGMPS-rhodamine. Data
represent the mean of three determinations ± SD (when larger than the circle diameter). The dashed line represents the dependence of % on cGMPS-rhodamine concentration
computed with the best-fitting value of Kd.
3.3. Binding equilibrium between PDE5C-TC and
cGMPS-rhodamine
Förster resonance energy transfer (FRET), the non-radiative
transfer of electronic excitation energy, has become widely
employed to study protein-protein and protein-ligand interactions
[28,29]. The FRET efficiency results from coupling between the
donor and the acceptor transition dipoles and, therefore, depends
on their relative orientation and decreases with the sixth power of
their distance [29]. Additionally, it depends on the spectral overlap
between the emission spectrum of the donor and the absorption
spectrum of the acceptor. For a given donor/acceptor pair, the
FRET efficiency is synthesized by the value of the Förster criti-
cal distance, i.e., the distance at which the FRET efficiency is 0.5
[29]. In this paper, we study the interaction between the catalytic
domain of PDE5C-TC, made fluorescent by binding of FlAsH, the
energy donor (D), at the tetracysteine motif and the pseudosusb-
trate cGMPS made fluorescent by conjugation to rhodamine (the
acceptor, A). We  developed a synthesis of cGMPS-rhodamine that
readily allowed access to milligram quantities of this compound.
FRET was then evaluated by measuring the intensity of the donor
(IF) in the absence and in the presence of the acceptor. To facil-
itate an understanding of the method, the rationale of the FRET
experiment is summarised in the cartoon in Fig. 3A.
To generate equilibrium binding curves, PDE5C-TC-FlAsH was
titrated with increasing amounts of cGMPS-rhodamine. Preferen-
tial excitation of FlAsH ($exc = 465 nm)  produced emission by FlAsH,
with maximum at 530 nm,  and triggered excitation energy-transfer
to rhodamine and subsequent emission from latter with maximum
at 600 nm.  The occurrence of FlAsH(D)-to-rhodamine(A) FRET in
PDE5C-TC-FlAsH/cGMPS-rhodamine complexes was  demonstrated
by the decrease of the D emission band at 530 nm and the concomi-
tant growth of the A emission band at 600 nm following addition
of cGMPS-rhodamine to a PDE5C-TC-FlAsH solution (Fig. 3B).
The observed I530 intensities (Iobs) were corrected in order to
account for the increasing absorbances of the added rhodamine at
the excitation and emission wavelengths (A465 and A530) as follows:
I530 = Iobs10(A465+A530)/2 (2)
and were used to determine the fraction of occupied binding sites,
%, in the PDE5-TC enzyme. This was  then plotted as a function of
the concentration of added cGMPS-rhodamine. In the non-linear
least squares regression analysis based on the standard Hill Eq. (3)
a value of n∼=1 was obtained, thus confirming a single binding site
for the substrate. (Fig. 3C).[
PDE5C − TC − FlAsH/cGMPS − rhodamine
]
[PDE5C − TC − FlAsH]tot
= % = Imax − I
Imax − I0 =
[cGMPS − rhodamine]n
Kd + [cGMPS − rhodamine]ntot
(3)
In Eq. (3), Kd is the apparent dissociation constant. Imax and I0 are
the maximum and the minimum values of the I530, respectively.
The value of Kd, obtained, 11.5 ± 1.5 "M,  is representative of a
noncovalent reversible interaction between the two  molecules, and
is consistent with the KM value of 10.7 "M obtained for [3H]cGMP
(see paragraph 3.1), which is in turn comparable with published
data [2].
3.4. Competitive displacement experiments
A competitive displacement experiment based on the equilib-
rium model and the above-established FRET-based technology was
then developed to test PDE5 inhibitor candidates and estimate their
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Fig. 4. A). Fluorometric titration of the PDE5C-TC-FlAsH/cGMPS-rhodamine complex with cGMPS at concentrations from 0 to 200 "M.  The arrows indicate the observed
signal  changes. B) Plot of the IF/IR intensity ratio (R throughout the text) as a function of the cGMPS concentration. The dotted line represents the R values calculated using
Kd = 10 "M for the PDE5C-TC-FlAsH/cGMPS complex. C) Fluorometric titration of the PDE5C-TC-FlAsH/cGMPS-rhodamine complex with Tadalafil concentrations from 0 to
30  "M.  The arrows indicate the increase in FlAsH (IF) and the decrease in the rhodamine (IR) signals associated with the decrease in FlAsH-to-rhodamine FRET efficiency due
to  displacement of cGMPS-rhodamine by tadalafil. D) Plot of the IF/IR intensity ratio (R throughout the text) as a function of the Tadalafil concentration. In panels B and D,
each  circle represents the mean of three determinations ± SD.
affinities. Since the Kd of the PCE5C-TC-FlAsH/cGMPS-rhodamine
(complex 1) has been obtained, the Kd of a competing inhibitor
can be estimated by measuring the relative occupancy of PDE5A
by cGMPS-rhodamine and the inhibitor. This can be accomplished
by evaluating the decrease in FlAsH-to-rhodamine FRET efficiency.
In order to increase the sensitivity of our approach, we exploited
both the expected experimental effects of the displacement, i.e., the
decrease in acceptor emission and the recovery of donor emission,
by computing the ratio of the 530 nm (IF) to 600 nm (IR) emission
intensities, R in Eq. (1) of paragraph 2.9, as a function of the inhibitor
concentration.
Complex 1 was obtained by combining 30 "M cGMPS-
rhodamine and 5 "M PDE5C-TC-FlAsH. At these concentrations, the
fraction of occupied PDE5C sites, and the FRET efficiency, are 0.7.
Complex 1 was then titrated with increasing amounts of catalytic-
site ligands.
We  tested this approach with two ligands that exhibit widely
differing affinities for the binding pocket of PDE5C, namely cGMPS
(presumably 10–12 "M)  and tadalafil (nanomolar).
cGMPS was added to complex 1 at concentrations from 0 to
200 "M.  We  observed an increase in the donor band intensity (IF)
together with a decrease in the acceptor band intensity (IR) (Fig. 4A),
indicating that cGMPS-rhodamine was displaced at the PDE5C-TC
binding site by cGMPS.The measured intensities are displayed, as
the IF/IR ratio, R, against the inhibitor concentration in Fig. 4B. As
outlined in paragraph 2.9, we then compared the experimental R
values with the R values calculated using Eq. (1), where the com-
plex 1 concentrations were obtained from the Wang corresponding
equation using tentative values for the equilibrium dissociation
constant of complex 2 [21,22]. The value of the dissociation con-
stant for the complex of the protein with the incoming ligand,
cGMPS thus estimated, Kd = 10 ± 2 "M,  is consistent with the corre-
sponding Kd value of complex 1 and the cGMP substrate KM value.
To test the method with a higher-affinity ligand, Tadalafil was
added to complex 1 at concentrations from 0 to 30 "M. Again, we
observed a recovery in the donor emission intensity together with
a decrease in the acceptor emission intensity, indicating displace-
ment of cGMPS-rhodamine from complex 1 due to formation of
complex 2 with Tadalafil (Fig. 4C). The IF/IR fluorescence intensity
ratios showed a behaviour consistent with quantitative binding of
Tadalafil to the protein, in agreement with the published nanomo-
lar affinity [30].
4. Conclusion
The FRET-based approach described here proved to be a valu-
able tool for detecting binding of small molecules to the catalytic
pocket of PDE5A. The approach is based on competitive cuvette-
based displacement experiments. The observables are the emission
intensities of an electronic excitation energy pair, namely, as the
donor, the fluorescein-based diarsenical probe, FlAsH, that binds
proteins that incorporate a CCPGCC motif and, as the acceptor,
rhodamine, that is covalently bound to a non-reactive substrate
analogue of this enzyme, cGMPS. Computational work proved the
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cGMPS-rhodamine conjugate thus obtained to bind the catalytic
pocket of the enzyme similarly to the natural substrate and pro-
vided some structural hints for the design of competitive inhibitors
of the PDE5 enzymes. Because the Kd value of the pseudosubstrate
ligand is 10 "M,  this displacement experiment is expected to rec-
ognize positives among compounds with Kd values for PDE5C from
tens of micromolar to nanomolar.
The approach is suitable for being adapted to a 96-well plate
format to be employed for medium-to-high throughput screen-
ings of new PDE5 competitive inhibitors, and for estimating their
potency. Removal of the excess FlAsH donor markedly increased the
observed FRET efficiency in our experiments and is thus expected to
result in a sensitive and robust assay. Extension of this approach to
cellular environments, following cloning of the PDE5C-TC construct
into a mammalian vector, is also easily foreseen and presently
underway in our laboratory.
Recent advances make this an exciting time for the research
on PDEs. In particular, these enzymes hold great promise as drug
targets. We believe that this new fluorescence-based tool can be
translated into a simple and robust assay for screening PDE binding-
pocket ligand libraries. To our knowledge this would be the only
such non-radiometric screening method available today.
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